Story perspectives
Semaglutide Reduces Heart Risks for Older Diabetics
10/20/2025
50 9
1 of 1
Story summary
- Semaglutide was associated with a 23% lower rate of major adverse cardiovascular events and a 26% lower risk of death compared with dulaglutide among older adults with type 2 diabetes and atherosclerotic cardiovascular disease.
- The analysis used real-world Medicare data on 58,336 patients.
- Older adults are often underrepresented in clinical trials.
- Further research across datasets and longer follow-up is needed to confirm the results.
